Reprogenix Bioscience
June 16, 2025
Company Presentation
Cell and Gene Therapy and Genome Editing
Reprogenix Bioscience’s lead candidate, RGB-5088, is chemically-induced pluripotent stem cell-derived islets (CiPSC-islets) with clinically-demonstrated safety and efficacy for diabetes therapy. Findings from the pilot clinical study of RGB-5088 was published in Cell [DOI: 10.1016/j.cell.2024.09.004], and showed for the first time rapid reversal of diabetes and insulin independence – as quickly as 75 days post-transplantation. RGB-5088 has received IND approval, and Phase 1 clinical trial has commenced, with Phase 2/3 trials anticipated to begin in 2026, and biologics license application projected for Oct 2027.
Reprogenix is led by Dr. Hongkui Deng – a world-renowned pioneer in regenerative medicine, particularly for his establishment of non-genetic cellular reprogramming technologies for which he was awarded the Future Science Prize in Life Sciences in 2024, Dr. Lieming Ding, pharmaceutical industry leader and innovator of oncology therapies, and biotech entrepeneur Ms. Casey Lou.
Company HQ City:
Hangzhou
Company HQ State:
Zhejiang
Company HQ Country:
China
Year Founded:
2014
Lead Product in Development:
RGB-5088, chemically-induced pluripotent stem cell-derived islets for diabetes therapy
CEO
Casey Lou, Co-founder and Managing Director
Dr. Lieming Ding, Co-founder and President
Prof. Hongkui Deng, Scientific Advisor
Development Phase of Lead Product
Phase I
What is your next catalyst (value inflection) update?
We have plans to raise 200 - 300 million CNY (27 - 41 million USD) by the end of June 2025 to advance our clinical pipeline and for optimizing bioprocesses.
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}